{"id":"W4205930483","doi":"10.1016/s2468-1253(21)00223-5","title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","year":2022,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":153,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"San Diego Digestive Diseases Research Center, School of Medicine, University of California, San Diego; Cilag; National Institute of Diabetes and Digestive and Kidney Diseases; Bristol-Myers Squibb; Samsung; Israel National Road Safety Authority; Vlaamse regering; Genentech; AstraZeneca; Allergan; Mylan; National Institutes of Health; Gilead Sciences; LEO Pharma; Novo Nordisk; Norgine; Fonds Wetenschappelijk Onderzoek; Mitsubishi Tanabe Pharma Corporation; Celltrion; Vifor Pharma; American Gastroenterological Association; Celgene; Pfizer; Biogen; Amgen; Eli Lilly and Company","keywords":"Therapeutic drug monitoring; Inflammatory bowel disease; Rheumatoid arthritis; Certolizumab pegol; Pharmacogenetics; Drug; Disease monitoring; Inflammatory Bowel Diseases; Clinical trial; Inflammatory arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005181882,0.0002867136,0.0004083317,0.000183295,0.0002055767,0.00001121372,0.0005769718,0.0001263,0.00003507576],"category_scores_gemma":[0.00002034142,0.0002528723,0.0001290797,0.000112451,0.0006084323,0.000008203174,0.0005642526,0.0004634696,0.000001747141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000585664,"about_ca_system_score_gemma":0.0001061038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001155545,"about_ca_topic_score_gemma":0.00009769218,"domain_scores_codex":[0.997333,0.0009934483,0.0003995355,0.0004949833,0.0001436977,0.0006352758],"domain_scores_gemma":[0.9989002,0.00003682094,0.0002347736,0.0006516086,0.00006221956,0.0001143731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002954258,0.00011748,0.9888113,0.00004037763,0.0001287189,0.000123084,0.0006333427,0.0001440652,0.005863282,0.0005900397,0.0004163044,0.0001777636],"study_design_scores_gemma":[0.001645802,0.0003060731,0.9876022,0.000005095344,0.00005415876,0.00008826537,0.00381603,0.0001413634,0.0001270907,0.0002919332,0.005754823,0.0001671624],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992566,0.004285986,0.00003750344,0.002100557,0.0005286442,0.0003273488,0.00008151534,0.00002629275,0.00004614026],"genre_scores_gemma":[0.9972081,0.0007815353,0.00006492786,0.0009624725,0.0006623825,0.0002065794,0.00004464807,0.00003161987,0.00003774497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005736191,"threshold_uncertainty_score":0.9999924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008345255838129437,"score_gpt":0.2347150561786161,"score_spread":0.2263698003404866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}